DE602006013029D1 - Anti-egfr-antikörper - Google Patents

Anti-egfr-antikörper

Info

Publication number
DE602006013029D1
DE602006013029D1 DE602006013029T DE602006013029T DE602006013029D1 DE 602006013029 D1 DE602006013029 D1 DE 602006013029D1 DE 602006013029 T DE602006013029 T DE 602006013029T DE 602006013029 T DE602006013029 T DE 602006013029T DE 602006013029 D1 DE602006013029 D1 DE 602006013029D1
Authority
DE
Germany
Prior art keywords
egfr
egfr antibody
antigen
binding portions
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006013029T
Other languages
English (en)
Inventor
Catherine Brautigam Beidler
Alain Philippe Vasserot
Jeffry Dean Watkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE602006013029D1 publication Critical patent/DE602006013029D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
DE602006013029T 2005-11-12 2006-11-06 Anti-egfr-antikörper Active DE602006013029D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73536305P 2005-11-12 2005-11-12
PCT/US2006/043311 WO2007058823A2 (en) 2005-11-12 2006-11-06 Anti-egfr antibodies

Publications (1)

Publication Number Publication Date
DE602006013029D1 true DE602006013029D1 (de) 2010-04-29

Family

ID=38049122

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006013029T Active DE602006013029D1 (de) 2005-11-12 2006-11-06 Anti-egfr-antikörper

Country Status (9)

Country Link
US (2) US7723484B2 (de)
JP (1) JP2009515878A (de)
AT (1) ATE461220T1 (de)
CA (1) CA2629095A1 (de)
DE (1) DE602006013029D1 (de)
DK (1) DK1951759T3 (de)
ES (1) ES2340205T3 (de)
PT (1) PT1951759E (de)
WO (1) WO2007058823A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092771A2 (en) 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20050158296A1 (en) 2002-01-11 2005-07-21 Starr Christopher M. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
MX2009006696A (es) * 2006-12-22 2009-06-30 Novelix Therapeutics Gmbh Tratamiento de diabetes con al menos un anticuerpo especifico del receptor del factor de crecimiento epidermico o uin derivado de este.
EP2126127B1 (de) 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Verwendung von anti-egfr-antikörpern bei der behandlung von durch egfr-mutanten vermittelten krankheiten
AU2008227123B2 (en) 2007-03-15 2014-03-27 Ludwig Institute For Cancer Research Ltd. Treatment method using EGFR antibodies and src inhibitors and related formulations
EP2188311B1 (de) 2007-08-14 2016-10-05 Ludwig Institute for Cancer Research Ltd. Auf den egf-rezeptor zielender, monoklonaler antikörper 175 und derivate und anwendungen davon
WO2010080463A1 (en) * 2008-12-18 2010-07-15 Imclone Llc Antibody humanization
CA2777825A1 (en) 2009-10-28 2011-05-19 Abbott Biotherapeutics Corp. Anti-egfr antibodies and their uses
CN101875695B (zh) * 2009-11-11 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 一种抗体及其编码基因与应用
MX346731B (es) 2010-04-23 2017-03-30 Genentech Inc * Producción de proteínas heteromultiméricas.
US9051370B2 (en) * 2010-08-10 2015-06-09 Glycotope Gmbh Humanized EGFR antibodies
RU2018108836A (ru) 2011-02-04 2019-03-14 Дженентек, Инк. ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
CA2840221A1 (en) 2011-07-05 2013-01-10 Bioasis Technologies Inc. P97-antibody conjugates and methods of use
DK2739649T3 (en) 2011-08-05 2018-01-08 Bioasis Technologies Inc P97 FRAGMENTS WITH TRANSFER ACTIVITY
US8791244B2 (en) * 2011-09-30 2014-07-29 Regeneron Pharmaceuticals, Inc. Anti-ErbB3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
SG11201405553YA (en) 2012-03-08 2014-11-27 Halozyme Inc Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
US9944707B2 (en) 2012-05-17 2018-04-17 Sorrento Therapeutics, Inc. Antibodies that bind epidermal growth factor receptor (EGFR)
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
US9932565B2 (en) 2012-07-31 2018-04-03 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
WO2014028221A1 (en) 2012-07-31 2014-02-20 Crown Bioscience, Inc. Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug
RU2648141C2 (ru) 2012-09-19 2018-03-22 Эббви Биотерапьютикс Инк. Способы идентификации антител с пониженной иммуногенностью
BR112015014621A2 (pt) * 2012-12-21 2017-10-03 Amplimmune Inc Anticorpos anti-h7cr
AU2014243816B2 (en) 2013-03-13 2019-01-31 Bioasis Technologies Inc. Fragments of p97 and uses thereof
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
CN105764924A (zh) 2013-09-12 2016-07-13 哈洛齐梅公司 修饰的抗表皮生长因子受体抗体及其使用方法
TW201609805A (zh) 2013-12-23 2016-03-16 美國禮來大藥廠 結合ｅｇｆｒ及ｍｅｔ之多功能抗體
ES2764973T3 (es) 2014-02-03 2020-06-05 Bioasis Technologies Inc Proteínas de fusión de P97
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
CN106413757B (zh) 2014-05-01 2022-01-14 比奥阿赛斯技术有限公司 p97-多核苷酸结合物
PT3148581T (pt) 2014-05-30 2020-01-06 Henlix Biotech Co Ltd Anticorpos antirrecetor do fator de crescimento epidérmico (egfr)
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
BR112018073739A2 (pt) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteína de ligação de albumina sérica de domínio único
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3589662A4 (de) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. Induzierbares monovalentes antigenbindendes protein
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
JP7425049B2 (ja) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． Ｄｌｌ３結合タンパク質および使用方法
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP2457586A1 (de) 2003-06-27 2012-05-30 Amgen Fremont Inc. Auf die Deletionsmutanten des epidermalen Wachstumsfaktorrezeptors gerichtete Antikörper und ihre Verwendungen

Also Published As

Publication number Publication date
PT1951759E (pt) 2010-04-01
JP2009515878A (ja) 2009-04-16
US20100166755A1 (en) 2010-07-01
ATE461220T1 (de) 2010-04-15
WO2007058823A3 (en) 2007-09-20
DK1951759T3 (da) 2010-05-10
US20080274114A1 (en) 2008-11-06
US7723484B2 (en) 2010-05-25
CA2629095A1 (en) 2007-05-24
ES2340205T3 (es) 2010-05-31
WO2007058823A2 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
DE602006013029D1 (de) Anti-egfr-antikörper
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
CY1116913T1 (el) Τροποποιημενα κλασματα fab αντισωματων
NO20074563L (no) Novel anti-plgf antibody
MA40913A (fr) Conjugués anticorps-médicament
ATE530195T1 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
CY1114658T1 (el) Πρωτεϊνες δεσμευσης αντιγονου του αυξητικου παραγοντα τυπου επιδερμικου αυξητικου παραγοντα προσδεσης στην ηπαρινη
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
EA200901500A1 (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
UA92504C2 (en) Anti-myostatin monoclonal antibody
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
TW200639182A (en) Antibody variants and uses thereof
DK2097453T3 (da) Monoklonale antistoffer mod humant Anti-Müllerian Hormon type II receptor (AMHR-II)
NZ594682A (en) Fully human antibodies specific to cadm1
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
MX2022002672A (es) Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
EA202090583A1 (ru) Композиции на основе антител против a33 и способы их применения в радиоиммунотерапии
UA102085C2 (ru) ВЫДЕЛЕННОЕ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С hGM-CSF, И КОМПОЗИЦИЯ МЕДИЦИНСКОГО НАЗНАЧЕНИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN